TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Dr. Carlos Ramos | EBMT 2018 | CD30-specific CAR redirected lymphocytes

By Sylvia Agathou

Share:

Featured:

Carlos RamosCarlos Ramos

Mar 26, 2018


44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, PT
Carlos Ramos
Baylor College of Medicine, Houston, TX, USA

  • Dr Ramos talks about recent work on CD30-specific CARs that is being developed in the treatment of lymphoma and other cancers.
  • He noted that there is a lot of data on CD19 however, other proteins have been more difficult to target.
  • From the study results, he found that chemotherapy given to patients before infusion showed improved activity and expansion and that lead to better results. 

Dr. Carlos Ramos | EBMT 2018 | CD30-specific CAR redirected lymphocytes